Microbiotica
Microbiotica develops oral medicines made from selected live bacteria for inflammatory diseases and cancer treatment.
£36MSeries C first close
LeadBB
British Business Bank
Activity from announced rounds
Activity in this selectionSeries C+
British Business Bank is the UK’s economic development bank, supporting business access to finance through investment programmes, funds and financing partners.
Its Future Fund: Breakthrough programme, delivered by British Patient Capital, co-invests with private investors in later-stage, R&D-intensive UK companies. It targets technologies such as quantum computing, cleantech and life sciences, where development requires substantial capital.
Applications to that programme come from a qualifying sponsor investor, rather than directly from the company. The published criteria require a round of at least £30 million, with the programme contributing no more than 30% on the sponsor investor’s terms.
- Rounds participated in
- 7
- Confirmed lead rounds
- 1 5 roles undisclosed
- New companies
- 7 First participation on record · 0 follow-on
- Funding in participating rounds
- $2.5B 6 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
7 in this selectionOMass Therapeutics
OMass Therapeutics develops small-molecule medicines for endocrine and immune diseases using a platform that measures drug targets in their biological surroundings.
$310MSeries C
ParticipantOxford Quantum Circuits
Develops superconducting quantum computers delivered via cloud for financial services, defence, and research customers
£260MSeries C
Role not disclosedElliptic
Provides on-chain analytics for digital assets
$120MSeries D
Role not disclosedQuantum Motion
Builds utility-scale quantum computers using industry-standard silicon transistors
$160MSeries C
Role not disclosedWayve
Provides end-to-end AI platform for autonomous driving licensed to automakers and mobility platforms
$1.5BSeries D
Role not disclosedNuclera
Provides rapid access to functional proteins through benchtop eProtein Discovery System
$12MSeries C+
Role not disclosed